— 01 · At a Glance
What is a DOTATATE PET scan?
★ In one paragraph
A DOTATATE PET scan (Ga-68 DOTATATE PET/CT) is a molecular imaging test that locates neuroendocrine tumours (NETs). A small amount of a radioactive tracer — 68Ga-DOTATATE, a somatostatin analogue — is injected into a vein. Because most well-differentiated NET cells carry large numbers of somatostatin receptors, they bind the tracer and appear as bright “hot spots,” fused with a CT for precise location.
One whole-body DOTATATE PET/CT can find the primary tumour (including a small primary that other scans miss), map how far it has spread, find an unknown primary when only metastases are seen, and — importantly — decide whether a patient is suitable for Lu-177 DOTATATE therapy (PRRT). It is the receptor-imaging counterpart for NETs of what the PSMA PET scan is for prostate cancer.
At Theranostic Physicians, DOTATATE PET/CT is performed in the Department of Nuclear Medicine at Fortis Memorial Research Institute (FMRI), Sector 44, Gurugram, with image interpretation led by Dr. Ishita B. Sen and Dr. Dharmender Malik.
— 02 · Machine & Reader
The scan is only as good as who reads it.
A DOTATATE PET result depends on two things working together: a good machine to acquire a clean, high-resolution study, and a good reader — an experienced nuclear medicine physician — to interpret it correctly. With DOTATATE this is especially true, because there are well-known traps in the normal pattern of uptake.
- The institution. Scans are performed at Fortis Memorial Research Institute, Sector 44, Gurugram — a leading tertiary hospital with a dedicated Department of Nuclear Medicine and modern PET/CT imaging.
- The reader. Every study is interpreted by Dr. Ishita B. Sen and Dr. Dharmender Malik. The spleen, pituitary, adrenal glands, kidneys and, in particular, the uncinate process of the pancreas all show normal DOTATATE uptake that can be mistaken for a tumour. Knowing these physiological pitfalls — and grading true tumour uptake for therapy — is exactly what focused experience provides.
A scan is only ever as reliable as the equipment that acquires it and the physician who reads it. We hold both to the same standard.
— 03 · Mechanism
How a DOTATATE PET works.
Somatostatin is a natural hormone that binds to somatostatin receptors on cells. Most well-differentiated neuroendocrine tumours overexpress these receptors — chiefly subtype 2 (SSTR2). A DOTATATE PET scan turns that biology into a picture:
- The tracer. DOTATATE is a laboratory-made somatostatin analogue. It is attached, through a linker called DOTA, to a positron-emitting radionuclide — usually Gallium-68 (a copper-64 version also exists).
- Injection. A small intravenous injection delivers the tracer. The amount of the peptide is a microdose, far too small to have a hormonal effect.
- Binding. Over roughly 45 to 60 minutes the tracer circulates and locks onto somatostatin receptors on neuroendocrine tumour cells wherever they are.
- Imaging. The PET scanner maps where the tracer has concentrated; the CT component adds precise anatomy. Receptor-rich disease appears as bright hot spots, and the strength of uptake is often graded against the normal liver and spleen using the Krenning score.
Some uptake is entirely normal: the spleen (the brightest normal structure), pituitary, adrenal glands, kidneys, liver and the uncinate process of the pancreas. Distinguishing this normal pattern from disease is a core part of expert reporting.
68Ga
DOTATATE PET MECHANISM
[Image: Infographic — Ga-68 DOTATATE somatostatin-analogue tracer binding somatostatin receptors on a neuroendocrine tumour cell, IV injection, ~45–60 min uptake, PET/CT acquisition showing receptor-avid hot spots]
— 04 · Indications
Who needs a DOTATATE PET scan?
A DOTATATE PET scan is requested by your oncologist, gastroenterologist or endocrinologist in several situations:
- Locating and staging a neuroendocrine tumour. For NETs of the small bowel (midgut carcinoid), pancreas, lung and elsewhere — to find the primary, map lymph-node and liver or bone spread, and plan treatment.
- Finding an unknown primary. When NET metastases are found (for example in the liver) but the original site is not known.
- Selecting patients for PRRT. To confirm a tumour is strongly somatostatin-receptor-positive before Lu-177 DOTATATE therapy (PRRT), and to map the disease beforehand.
- Restaging and follow-up. To reassess the extent of disease or check for recurrence.
- Related receptor-positive tumours. Selected cases of phaeochromocytoma, paraganglioma and some other somatostatin-receptor-expressing tumours.
★ When DOTATATE isn't enough — the FDG companion
DOTATATE images well-differentiated NETs, which are rich in somatostatin receptors. High-grade or poorly differentiated neuroendocrine tumours often lose these receptors and may show little DOTATATE uptake — while becoming more avid on an FDG PET scan. In higher-grade or aggressive disease the two scans are sometimes used together (dual-tracer imaging) to capture the full, sometimes mixed, behaviour of the tumour before a treatment decision.
— 05 · The Visit
What to expect on the day.
A DOTATATE PET scan is an outpatient test. Plan for about one and a half to two hours at the centre — most of it the quiet uptake period. The scan itself is short and painless.
01
Before you arrive
No fasting is required. The key point is medication: if you take a somatostatin analogue (octreotide or lanreotide), tell us. Short-acting octreotide is usually withheld for about 24 hours, and the scan is timed around any long-acting (depot) injection so it does not dampen the images. Stay hydrated.
02
Tracer injection
A small intravenous injection of 68Ga-DOTATATE. It is painless beyond the needle prick. There is no sedation and none of the contrast-dye reaction risk associated with iodinated CT dye.
03
Uptake — rest ~45–60 minutes
You rest quietly while the tracer binds to somatostatin receptors throughout the body. You may be asked to empty your bladder just before imaging.
04
The scan & the read
A whole-body PET/CT acquisition of about 20 to 30 minutes — you simply lie still. Afterwards, resume normal activity and drink fluids to clear the tracer. Dr. Sen and Dr. Malik interpret the images and issue the report.
Out-of-town and international patients are helped with scheduling so the scan, the review and any onward plan can be arranged in a single short trip.
— 06 · Accuracy
What a DOTATATE PET shows — and how it compares.
DOTATATE PET/CT changed neuroendocrine tumour imaging because it images the receptor the tumour carries, directly and sensitively.
How it compares
- Versus the older OctreoScan. Ga-68 DOTATATE PET/CT has higher sensitivity and sharper images than In-111 OctreoScan (somatostatin receptor scintigraphy), is done in one visit instead of two days, and uses less radiation — so it has largely replaced it.
- Versus CT and MRI alone. It detects receptor-positive disease — small primaries, nodal and distant spread — that conventional anatomical imaging can miss, and frequently changes the management plan.
Its limitations
- Grade matters. DOTATATE relies on somatostatin receptors, which well-differentiated NETs express but high-grade, poorly differentiated tumours may lose — these can be DOTATATE-negative and are better seen on an FDG PET scan.
- Normal-uptake pitfalls. Physiological uptake in the spleen, pituitary, adrenals, kidneys and the pancreatic uncinate process can mimic disease and must be recognised by the reader.
- Not every hot spot is a tumour. Some inflammatory and other conditions can show uptake, so findings are always read against your history and other tests.
For how molecular PET differs from an ordinary anatomical scan, see PET scan vs CT scan.
— 07 · See-and-Treat
From scan to therapy.
A DOTATATE PET scan is not only diagnostic — it is the gateway to treatment, and the clearest example of theranostics in NET care. The very same somatostatin receptor that the scan lights up is what the therapy binds to and irradiates.
If the scan shows strong receptor-positive disease, you may be a candidate for Lu-177 DOTATATE therapy (PRRT) — peptide receptor radionuclide therapy, which delivers radiation directly to somatostatin-receptor-expressing tumour cells. Its benefit in advanced midgut NETs was established in the randomised NETTER-1 trial. In selected cases, Ac-225 DOTATATE alpha therapy is a further option. The diagnostic scan and the therapy are deliberately matched: the tracer and the treatment differ only in the radionuclide they carry.
If you already have DOTATATE PET images from elsewhere and want an independent expert opinion before deciding, our Second Read service provides a formal re-read of your existing study.
— 08 · Pricing
Cost of a DOTATATE PET scan in India.
The Ga-68 DOTATATE PET/CT scan is billed by Fortis Memorial Research Institute. The price you pay is the same hospital counter price for everyone — with no commission added for booking and coordinating through our team. We do not discount; the value is in the accuracy of the scan and the physician who reads it.
| Scan |
Cost |
Includes |
|
Ga-68 DOTATATE PET/CT (whole body)
|
₹ [ ADD PRICE ] |
Tracer + whole-body PET/CT + expert report |
★ How pricing works
Pricing is set and billed by FMRI and may change. A written quote covering the tracer, the whole-body PET/CT and the expert report is issued on enquiry. See current scan pricing on our PET-CT scan service page, or WhatsApp +91 8700 668431 for a written estimate.
— 09 · Safety
Is a DOTATATE PET scan safe?
Yes — a DOTATATE PET scan is a very safe, well-tolerated test. It is non-invasive apart from a single small injection.
Tracer & side effects
- The DOTATATE tracer is given in a microdose; allergic or adverse reactions are rare and usually mild.
- There is no sedation and none of the contrast-dye reactions associated with iodinated CT contrast.
- You can eat, drink and drive as normal afterwards. Drinking fluids helps flush the tracer, which is cleared mainly through the kidneys.
Radiation
- The radiation dose is low — in the range of other routine diagnostic PET/CT studies, lower than the older OctreoScan, and a small fraction of any therapeutic dose.
- The radioactivity decays quickly. As a routine precaution we may advise limiting prolonged close contact with pregnant women and young children for a few hours after the scan.
Medication, pregnancy & breastfeeding
- Tell the team about any somatostatin analogue (octreotide or lanreotide) so the scan can be timed correctly.
- Tell the team beforehand if there is any possibility of pregnancy or if you are breastfeeding, so appropriate precautions can be taken.
— 10 · Booking
Book a DOTATATE PET scan.
Ga-68 DOTATATE PET/CT is performed at the Department of Nuclear Medicine, Fortis Memorial Research Institute, Sector 44, Gurugram — the single centre where we deliver scans — with interpretation led by Dr. Ishita B. Sen and Dr. Dharmender Malik. Our team coordinates directly with the department so you skip the phone queues, and can usually secure a priority slot on a best-effort basis.
★ Referrals welcome
We accept and welcome referrals from your treating physician — oncologist, gastroenterologist, endocrinologist, surgeon or family doctor. If you are a clinician referring a patient, contact us directly and we will coordinate scheduling and ensure the report reaches you. Patients may also arrange a scan directly; we always share the final report with your treating doctor so your care stays joined up.
★ How to book
Message the coordination team on WhatsApp +91 8700 668431 or email info@nuclearmedicinetherapy.in with your name, city, and a brief history (diagnosis, tumour grade if known, current medication, and whether this is for staging, follow-up or therapy planning). We confirm the slot, the medication timing, the price quote and the preparation. Out-of-town and international patients are helped with scheduling and logistics.
Already have DOTATATE PET images from another centre? You can request an independent expert opinion through our Second Read service without travelling.
Frequently asked questions.
A DOTATATE PET scan (Ga-68 DOTATATE PET/CT) is a molecular imaging test that locates neuroendocrine tumours. A small amount of a radioactive tracer called 68Ga-DOTATATE — a somatostatin analogue — is injected into a vein. Most well-differentiated neuroendocrine tumour cells carry large numbers of somatostatin receptors, so they bind the tracer and appear as bright spots, fused with a CT for precise location.
It shows where somatostatin-receptor-positive disease is in the body. It is used mainly for neuroendocrine tumours — of the small bowel, pancreas and lung, and carcinoid tumours — to find the primary, detect metastases, stage the disease, find an unknown primary, and select patients for Lu-177 DOTATATE therapy (PRRT). It is also used for some related tumours such as phaeochromocytoma and paraganglioma that express somatostatin receptors.
For neuroendocrine tumours, yes. Ga-68 DOTATATE PET/CT has higher sensitivity and better resolution than the older In-111 OctreoScan (somatostatin receptor scintigraphy), is completed in a single visit rather than over two days, and involves less radiation. Because it detects more disease, it has largely replaced OctreoScan and frequently changes the treatment plan.
Fasting is generally not required. The main consideration is medication: if you take a somatostatin analogue (octreotide or lanreotide), tell the team. Short-acting octreotide is usually withheld for about 24 hours, and the scan is timed around any long-acting (depot) injection so it does not interfere with the images. Stay hydrated. Your exact instructions are confirmed when the scan is booked.
Plan for about one and a half to two hours at the centre. After the injection there is an uptake period of roughly 45 to 60 minutes while the tracer binds to somatostatin receptors, followed by the scan itself, which takes about 20 to 30 minutes. The imaging is painless — you simply lie still.
At FMRI Sector 44, Gurugram, the scan is billed by the hospital at the same counter price for everyone, with no commission. A written quote covering the tracer, the whole-body PET/CT and the expert report is provided on enquiry — see the PET-CT scan service page or WhatsApp +91 8700 668431.
Yes. The tracer is given in a tiny (microdose) amount and adverse reactions are rare and usually mild. The radiation dose is low — comparable to other diagnostic PET/CT studies, lower than the older OctreoScan, and far below any treatment dose. Drink fluids afterwards to help clear the tracer, which decays quickly.
It means the tumour expresses somatostatin receptors strongly enough to take up the tracer. This matters because the same receptor can be used for treatment: strong uptake — often graded against the normal liver and spleen with the Krenning score — indicates a patient may be suitable for Lu-177 DOTATATE therapy (PRRT). Some high-grade or poorly differentiated tumours lose the receptor and show little uptake, in which case an FDG PET scan may be added.
Ga-68 DOTATATE PET/CT is performed at the Department of Nuclear Medicine, Fortis Memorial Research Institute, Sector 44, Gurugram, with interpretation led by Dr. Ishita B. Sen and Dr. Dharmender Malik. Appointments are coordinated on WhatsApp +91 8700 668431, and referrals from treating physicians are welcome. Out-of-town and international patients are helped with scheduling and logistics.
Written & Medically Reviewed By
Dr. Ishita B. Sen
MBBS · DRM · DNB (Nuclear Medicine) · 30+ years in nuclear oncology
Director and Head, Department of Nuclear Medicine and Molecular Imaging, Fortis Memorial Research Institute. Visiting fellowships at Memorial Sloan Kettering Cancer Center, New York and University of Marburg, Germany. Past President, Association of Nuclear Medicine Physicians of India. Co-author on published Indian protocols for PET imaging and theranostics.
FellowshipsMSK New York · Marburg
Past PresidentANMPI
SpecialityTheranostics & PET/CT Imaging
Full profile
References & citations
- Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of 68Ga-DOTATATE PET/CT compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. Journal of Nuclear Medicine, 2016;57(6):872–878.
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1). New England Journal of Medicine, 2017;376(2):125–135. DOI: 10.1056/NEJMoa1607427
- Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 2017;44(9):1588–1601.
- Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. Journal of Nuclear Medicine, 2018;59(1):66–74.